Innate Pharma S.A. (IPHA)
NASDAQ: IPHA · Real-Time Price · USD
2.270
+0.065 (2.95%)
Aug 25, 2026, 4:00 PM EDT - Market closed
Innate Pharma Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, Innate Pharma stock has a consensus rating of "Strong Buy" and an average price target of $7.00. The average 1-year stock price forecast is 208.37% higher than the current stock price, while the lowest is $4.00 (+76.21%) and the highest is $9.00 (+296.48%).
Price Target: $7.00 (+208.37%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Innate Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 3 | 3 | 3 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 3 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Buy Maintains $8 → $9 | Buy | Maintains | $8 → $9 | +296.48% | Aug 11, 2026 |
| Leerink Partners | Leerink Partners | Buy Upgrades $3 → $4 | Buy | Upgrades | $3 → $4 | +76.21% | Aug 11, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $5 → $7 | Buy | Reiterates | $5 → $7 | +208.37% | Aug 10, 2026 |
Financial Forecast
Revenue This Year
40.33M
from 9.01M
Increased by 347.85%
Revenue Next Year
96.63M
from 40.33M
Increased by 139.60%
EPS This Year
0.95
EPS Next Year
2.15
from 0.95
Increased by 126.32%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EUR.